Computational systems biology approaches to anti-angiogenic cancer therapeutics.

Angiogenesis is an exquisitely regulated process that is required for physiological processes and is also important in numerous diseases. Tumors utilize angiogenesis to generate the vascular network needed to supply the cancer cells with nutrients and oxygen, and many cancer drugs aim to inhibit tumor angiogenesis. Anti-angiogenic therapy involves inhibiting multiple cell types, molecular targets, and intracellular signaling pathways. Computational tools are useful in guiding treatment strategies, predicting the response to treatment, and identifying new targets of interest. Here, we describe progress that has been made in applying mathematical modeling and bioinformatics approaches to study anti-angiogenic therapeutics in cancer.

[1]  H. Gerhardt,et al.  Endothelial cells dynamically compete for the tip cell position during angiogenic sprouting , 2010, Nature Cell Biology.

[2]  Jana L. Gevertz,et al.  Computational Modeling of Tumor Response to Vascular-Targeting Therapies—Part I: Validation , 2011, Comput. Math. Methods Medicine.

[3]  Aleksander S. Popel,et al.  Collagen IV and CXC chemokine-derived antiangiogenic peptides suppress glioma xenograft growth , 2012, Anti-cancer drugs.

[4]  Murtaza M Tambuwala,et al.  A dynamic model of the hypoxia-inducible factor 1&agr; (HIF-1&agr;) network , 2013, Journal of Cell Science.

[5]  Veronika Bordas,et al.  Identifying therapeutic targets in a combined EGFR-TGFβR signalling cascade using a multiscale agent-based cancer model. , 2012, Mathematical medicine and biology : a journal of the IMA.

[6]  Aleksander S. Popel,et al.  Targeting Neuropilin-1 to Inhibit VEGF Signaling in Cancer: Comparison of Therapeutic Approaches , 2006, PLoS Comput. Biol..

[7]  Aleksander S Popel,et al.  Inhibition of lymphangiogenesis and angiogenesis in breast tumor xenografts and lymph nodes by a peptide derived from transmembrane protein 45A. , 2013, Neoplasia.

[8]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumours , 2013 .

[9]  Ricky T. Tong,et al.  Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  David W. Smith,et al.  On the role of diffusible binding partners in modulating the transport and concentration of proteins in tissues. , 2010, Journal of theoretical biology.

[11]  Emmanouil D Karagiannis,et al.  Distinct modes of collagen type I proteolysis by matrix metalloproteinase (MMP) 2 and membrane type I MMP during the migration of a tip endothelial cell: insights from a computational model. , 2006, Journal of theoretical biology.

[12]  Rakesh K Jain,et al.  Can we identify predictive biomarkers for antiangiogenic therapy of cancer using mathematical modeling? , 2013, Journal of the National Cancer Institute.

[13]  B. Schoeberl,et al.  Optimizing properties of antireceptor antibodies using kinetic computational models and experiments. , 2012, Methods in enzymology.

[14]  V. Ellenrieder,et al.  Primers on Molecular Pathways – The NFAT Transcription Pathway in Pancreatic Cancer , 2010, Pancreatology.

[15]  Karen M Page,et al.  Mathematical models of the VEGF receptor and its role in cancer therapy , 2007, Journal of The Royal Society Interface.

[16]  A. Popel,et al.  Computational Model of Gab1/2-Dependent VEGFR2 Pathway to Akt Activation , 2013, PloS one.

[17]  Wentao Yan,et al.  Numerical Simulation of the Inhibitory Effect of Angiostatin on Metastatic Tumor Angiogenesis and Microenvironment , 2013, Bulletin of mathematical biology.

[18]  Aleksander S. Popel,et al.  Pharmacokinetics and pharmacodynamics of VEGF-neutralizing antibodies , 2011, BMC Systems Biology.

[19]  Hulin Wu,et al.  Multi-scale agent-based modeling on melanoma and its related angiogenesis analysis , 2013, Theoretical Biology and Medical Modelling.

[20]  Thimo Rohlf,et al.  Receptor cross-talk in angiogenesis: mapping environmental cues to cell phenotype using a stochastic, Boolean signaling network model. , 2010, Journal of theoretical biology.

[21]  Florence T. H. Wu,et al.  Increase of plasma VEGF after intravenous administration of bevacizumab is predicted by a pharmacokinetic model. , 2010, Cancer research.

[22]  Manuel Mayr,et al.  MicroRNAs in vascular and metabolic disease. , 2012, Circulation research.

[23]  G. Taraboletti,et al.  Targeting angiogenesis with compounds from the extracellular matrix. , 2011, The international journal of biochemistry & cell biology.

[24]  Aleksander S Popel,et al.  Constructing the angiome: a global angiogenesis protein interaction network. , 2012, Physiological genomics.

[25]  Ricky T. Tong,et al.  Effect of vascular normalization by antiangiogenic therapy on interstitial hypertension, peritumor edema, and lymphatic metastasis: insights from a mathematical model. , 2007, Cancer research.

[26]  Stacey D. Finley,et al.  Predicting the Effects of Anti-angiogenic Agents Targeting Specific VEGF Isoforms , 2012, The AAPS Journal.

[27]  H. Westerhoff,et al.  Mathematical modelling of miRNA mediated BCR.ABL protein regulation in chronic myeloid leukaemia vis-a-vis therapeutic strategies. , 2013, Integrative biology : quantitative biosciences from nano to macro.

[28]  A. Clyne,et al.  A Computational Model of Fibroblast Growth Factor-2 Binding to Endothelial Cells Under Fluid Flow , 2012, Annals of Biomedical Engineering.

[29]  A. Popel,et al.  Computational model of VEGFR2 pathway to ERK activation and modulation through receptor trafficking. , 2013, Cellular signalling.

[30]  Didier Bresch,et al.  A pharmacologically based multiscale mathematical model of angiogenesis and its use in investigating the efficacy of a new cancer treatment strategy. , 2009, Journal of theoretical biology.

[31]  A. Popel,et al.  A Biochemical Model of Matrix Metalloproteinase 9 Activation and Inhibition* , 2007, Journal of Biological Chemistry.

[32]  P. K. Mainib,et al.  Modelling the Role of Angiogenesis and Vasculogenesis in Solid Tumour Growth , 2007 .

[33]  E. Chautard,et al.  Molecular Interplay between Endostatin, Integrins, and Heparan Sulfate* , 2009, The Journal of Biological Chemistry.

[34]  Aleksander S Popel,et al.  A bioimage informatics based reconstruction of breast tumor microvasculature with computational blood flow predictions. , 2014, Microvascular research.

[35]  R. Jain,et al.  A mathematical model of the contribution of endothelial progenitor cells to angiogenesis in tumors: implications for antiangiogenic therapy. , 2003, Blood.

[36]  Prahlad T. Ram,et al.  Cancer Systems Biology: a peek into the future of patient care? , 2014, Nature Reviews Clinical Oncology.

[37]  Aleksander S Popel,et al.  Anti-angiogenic peptides for cancer therapeutics. , 2011, Current pharmaceutical biotechnology.

[38]  Katie Bentley,et al.  Predicting the future: towards symbiotic computational and experimental angiogenesis research. , 2013, Experimental cell research.

[39]  Shanling Xu,et al.  The NF-κB activation pathways, emerging molecular targets for cancer prevention and therapy , 2010, Expert opinion on therapeutic targets.

[40]  L. Reynolds,et al.  Integrins: the keys to unlocking angiogenesis. , 2008, Arteriosclerosis, thrombosis, and vascular biology.

[41]  Durjoy Majumder,et al.  Dynamical model for assessment of anti-angiogenic therapy of cancer. , 2010, Molecular bioSystems.

[42]  J. Nör,et al.  Quantification of endothelial cell–targeted anti–Bcl-2 therapy and its suppression of tumor growth and vascularization , 2009, Molecular Cancer Therapeutics.

[43]  Aleksander S. Popel,et al.  Quantifying the Proteolytic Release of Extracellular Matrix-Sequestered VEGF with a Computational Model , 2010, PloS one.

[44]  Aleksander S Popel,et al.  A systems biology view of blood vessel growth and remodelling , 2013, Journal of cellular and molecular medicine.

[45]  Aleksander S. Popel,et al.  Formation of VEGF isoform-specific spatial distributions governing angiogenesis: computational analysis , 2011, BMC Systems Biology.

[46]  F. Giuliani,et al.  Critical Appraisal of Ramucirumab (IMC-1121B) for Cancer Treatment: From Benchside to Clinical Use , 2013, Drugs.

[47]  M. Kudo,et al.  Signaling Pathways Governing Tumor Angiogenesis , 2011, Oncology.

[48]  F. Berger,et al.  MicroRNAs: molecular features and role in cancer. , 2012, Frontiers in bioscience.

[49]  Xiaobo Zhou,et al.  Multi-scale agent-based brain cancer modeling and prediction of TKI treatment response: Incorporating EGFR signaling pathway and angiogenesis , 2012, BMC Bioinformatics.

[50]  Aleksander S Popel,et al.  Novel peptide-specific quantitative structure-activity relationship (QSAR) analysis applied to collagen IV peptides with antiangiogenic activity. , 2011, Journal of medicinal chemistry.

[51]  R. Danesi,et al.  Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer , 2011, British Journal of Cancer.

[52]  S. Falco.  Antiangiogenesis therapy: an update after the first decade. , 2014 .

[53]  Frédéric Dayan,et al.  Gene regulation in response to graded hypoxia: the non-redundant roles of the oxygen sensors PHD and FIH in the HIF pathway. , 2009, Journal of theoretical biology.

[54]  Bertram Klinger,et al.  Supplementary Materials for : Network quantification of EGFR signaling unveils potential for targeted combination therapy , 2022 .

[55]  H. Byrne.  Dissecting cancer through mathematics: from the cell to the animal model , 2010, Nature Reviews Cancer.

[56]  G. Semenza.  Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy. , 2012, Trends in pharmacological sciences.

[57]  R. Jain.  Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[58]  M. L. Tanaka,et al.  Coupled mathematical model of tumorigenesis and angiogenesis in vascular tumours , 2010, Cell proliferation.

[59]  H. Hurwitz,et al.  Anti-VEGF therapies in the clinic. , 2012, Cold Spring Harbor perspectives in medicine.

[60]  R. Basha,et al.  Expression of specificity protein transcription factors in pancreatic cancer and their association in prognosis and therapy. , 2012, Current medicinal chemistry.

[61]  Robert Jeraj,et al.  Computational modelling of anti-angiogenic therapies based on multiparametric molecular imaging data , 2012, Physics in medicine and biology.

[62]  P. LoRusso,et al.  Icrucumab, a fully human monoclonal antibody against the vascular endothelial growth factor receptor-1, in the treatment of patients with advanced solid malignancies: a Phase 1 study , 2014, Investigational New Drugs.

[63]  P. LoRusso,et al.  A Phase Ib study evaluating MNRP1685A, a fully human anti-NRP1 monoclonal antibody, in combination with bevacizumab and paclitaxel in patients with advanced solid tumors , 2014, Cancer Chemotherapy and Pharmacology.

[64]  R. Karchin,et al.  Collections of simultaneously altered genes as biomarkers of cancer cell drug response. , 2013, Cancer research.

[65]  Greg M Thurber,et al.  A mechanistic compartmental model for total antibody uptake in tumors. , 2012, Journal of theoretical biology.

[66]  Olaf Wolkenhauer,et al.  MicroRNA-regulated networks: the perfect storm for classical molecular biology, the ideal scenario for systems biology. , 2013, Advances in experimental medicine and biology.

[67]  Yuri Kogan,et al.  A new validated mathematical model of the Wnt signalling pathway predicts effective combinational therapy by sFRP and Dkk. , 2012, The Biochemical journal.

[68]  Young-Guen Kwon,et al.  The Wnt pathway and the roles for its antagonists, DKKS, in angiogenesis , 2012, IUBMB life.

[69]  X. Chen,et al.  Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. , 2011, The Journal of clinical investigation.

[70]  P. Carmeliet,et al.  Markers of response for the antiangiogenic agent bevacizumab. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[71]  Harsh V Jain,et al.  Modeling the VEGF–Bcl-2–CXCL8 Pathway in Intratumoral Agiogenesis , 2008, Bulletin of mathematical biology.

[72]  Aleksander S. Popel,et al.  Synergy between a collagen IV mimetic peptide and a somatotropin-domain derived peptide as angiogenesis and lymphangiogenesis inhibitors , 2012, Angiogenesis.

[73]  David Haussler,et al.  Inference of patient-specific pathway activities from multi-dimensional cancer genomics data using PARADIGM , 2010, Bioinform..

[74]  Stacey D. Finley,et al.  Effect of tumor microenvironment on tumor VEGF during anti-VEGF treatment: systems biology predictions. , 2013, Journal of the National Cancer Institute.

[75]  Zhihui Wang,et al.  Cross-scale, cross-pathway evaluation using an agent-based non-small cell lung cancer model , 2009, Bioinform..

[76]  Gordon B Mills,et al.  Bioinformatics and systems biology , 2012, Molecular oncology.

[77]  Aleksander S Popel,et al.  Extracellular regulation of VEGF: isoforms, proteolysis, and vascular patterning. , 2014, Cytokine & growth factor reviews.

[78]  Napoleone Ferrara,et al.  Antiangiogenic Therapy for Cancer: An Update , 2007, Cancer journal.

[79]  Emmanouil D Karagiannis,et al.  A systematic methodology for proteome-wide identification of peptides inhibiting the proliferation and migration of endothelial cells , 2008, Proceedings of the National Academy of Sciences.

[80]  H. Burris,et al.  Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway , 2013, Cancer Chemotherapy and Pharmacology.

[81]  Yiling Lu,et al.  Identification of optimal drug combinations targeting cellular networks: integrating phospho-proteomics and computational network analysis. , 2010, Cancer research.

[82]  M J Plank,et al.  A reinforced random walk model of tumour angiogenesis and anti-angiogenic strategies. , 2003, Mathematical medicine and biology : a journal of the IMA.

[83]  D. Ribatti.  Endogenous inhibitors of angiogenesis: a historical review. , 2009, Leukemia research.

[84]  Robert Jeraj,et al.  An imaging-based tumour growth and treatment response model: investigating the effect of tumour oxygenation on radiation therapy response , 2008, Physics in medicine and biology.

[85]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumors , 2012, Nature.

[86]  Thomas L. Jackson,et al.  A CONTINUOUS MODEL OF ANGIOGENESIS: INITIATION, EXTENSION, AND MATURATION OF NEW BLOOD VESSELS MODULATED BY VASCULAR ENDOTHELIAL GROWTH FACTOR, ANGIOPOIETINS, PLATELET-DERIVED GROWTH FACTOR-B, AND PERICYTES , 2013 .

[87]  Aleksander S Popel,et al.  Serpin-derived peptides are antiangiogenic and suppress breast tumor xenograft growth. , 2012, Translational oncology.

[88]  T. Chou.  Drug combination studies and their synergy quantification using the Chou-Talalay method. , 2010, Cancer research.

[89]  Emmanouil D Karagiannis,et al.  A Theoretical Model of Type I Collagen Proteolysis by Matrix Metalloproteinase (MMP) 2 and Membrane Type 1 MMP in the Presence of Tissue Inhibitor of Metalloproteinase 2*[boxs] , 2004, Journal of Biological Chemistry.

[90]  Andrei Zinovyev,et al.  Mathematical modeling of microRNA-mediated mechanisms of translation repression. , 2012, Advances in experimental medicine and biology.

[91]  Wei Zhang,et al.  The Pleiotropic Effects of miRNAs on Tumor Angiogenesis , 2015, Journal of cellular biochemistry.

[92]  Aleksander S. Popel,et al.  Reactive Oxygen Species Regulate Hypoxia-Inducible Factor 1α Differentially in Cancer and Ischemia , 2008, Molecular and Cellular Biology.

[93]  C. Gialeli,et al.  Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting , 2011, The FEBS journal.

[94]  T. Kume.  The Role of FoxC2 Transcription Factor in Tumor Angiogenesis , 2011, Journal of oncology.

[95]  L. Cardon,et al.  Use of genome-wide association studies for drug repositioning , 2012, Nature Biotechnology.

[96]  A.A. Qutub,et al.  Multiscale models of angiogenesis , 2009, IEEE Engineering in Medicine and Biology Magazine.

[97]  F. M. Gabhann,et al.  Simulating Therapeutics Using Multiscale Models of the VEGF Receptor System in Cancer , 2012 .

[98]  T. Bastogne,et al.  Tumor vascular responses to antivascular and antiangiogenic strategies: looking for suitable models. , 2012, Trends in biotechnology.

[99]  O. Volpert,et al.  Therapies using anti-angiogenic peptide mimetics of thrombospondin-1 , 2011, Expert opinion on therapeutic targets.

[100]  Colin Phipps,et al.  Mathematical Model of the Effect of Interstitial Fluid Pressure on Angiogenic Behavior in Solid Tumors , 2011, Comput. Math. Methods Medicine.

[101]  Feng Chen,et al.  Identifying targets for drug discovery using bioinformatics , 2008, Expert opinion on therapeutic targets.